Disc Medicine, Inc. (IRON) Insider Trading Activity

NASDAQ$76.33
Market Cap
$2.88B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
649 of 893
Rank in Industry
376 of 511

IRON Insider Trading Activity

IRON Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$89,249,058
50
100

Related Transactions

Stephenson PamelaChief Commercial Officer
0
$0
1
$171,217
$-171,217
Franchi Jean M.Chief Financial Officer
0
$0
4
$510,511
$-510,511
Khara RahulChief Legal Officer
0
$0
4
$1.06M
$-1.06M
Savage William JacobChief Medical Officer
0
$0
5
$1.87M
$-1.87M
Yu Jonathan Yen-WenChief Operating Officer
0
$0
2
$2.63M
$-2.63M
Quisel John DChief Executive Officer
0
$0
4
$6.24M
$-6.24M
Ashiya Monadirector
0
$0
7
$20.11M
$-20.11M
ORBIMED ADVISORS LLCdirector
0
$0
7
$20.11M
$-20.11M
Bitterman Kevindirector
0
$0
16
$36.55M
$-36.55M

About Disc Medicine, Inc.

Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. It builds a portfolio of therapeutic candidates that address a spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, primarily heme biosynthesis and iron homeostasis. The company is based in Watertown, Massachusetts.

Insider Activity of Disc Medicine, Inc.

Over the last 12 months, insiders at Disc Medicine, Inc. have bought $0 and sold $89.25M worth of Disc Medicine, Inc. stock.

On average, over the past 5 years, insiders at Disc Medicine, Inc. have bought $12M and sold $49.27M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 222,223 shares for transaction amount of $8M was made by Bitterman Kevin (director) on 2024‑06‑17.

List of Insider Buy and Sell Transactions, Disc Medicine, Inc.

2026-01-20SaleKhara RahulChief Legal Officer
1,000
0.0025%
$69.74
$69,740
+7.59%
2026-01-02SaleKhara RahulChief Legal Officer
6,500
0.0171%
$78.69
$511,472
-2.36%
2025-12-17SaleBitterman Kevindirector
754
0.0021%
$91.47
$68,968
-10.16%
2025-12-16SaleBitterman Kevindirector
68,923
0.1821%
$91.24
$6.29M
-14.04%
2025-12-15SaleSavage William JacobChief Medical Officer
13,093
0.0344%
$91.22
$1.19M
-14.32%
2025-12-15SaleBitterman Kevindirector
69,693
0.1833%
$91.34
$6.37M
-14.32%
2025-12-12SaleBitterman Kevindirector
45,507
0.1212%
$92.39
$4.2M
-13.97%
2025-12-11SaleQuisel John DChief Executive Officer
40,000
0.1054%
$93.05
$3.72M
-15.54%
2025-11-11SaleYu Jonathan Yen-WenChief Operating Officer
30,000
0.0803%
$84.70
$2.54M
+1.13%
2025-10-17SaleBitterman Kevindirector
70,000
0.1991%
$88.91
$6.22M
-4.25%
2025-10-16SaleBitterman Kevindirector
1,425
0.0043%
$77.11
$109,882
+15.88%
2025-10-15SaleBitterman Kevindirector
22,160
0.0639%
$77.23
$1.71M
+11.87%
2025-10-08SaleBitterman Kevindirector
71,961
0.2079%
$70.58
$5.08M
+22.40%
2025-10-07SaleBitterman Kevindirector
18,039
0.0523%
$68.38
$1.23M
+26.51%
2025-08-22SaleBitterman Kevindirector
2,287
0.0067%
$61.03
$139,576
+31.05%
2025-08-14SaleBitterman Kevindirector
7,212
0.0208%
$60.99
$439,860
+29.39%
2025-08-13SaleBitterman Kevindirector
24,962
0.0719%
$61.15
$1.53M
+28.36%
2025-08-05SaleBitterman Kevindirector
395
0.0011%
$60.95
$24,075
+26.94%
2025-07-30SaleBitterman Kevindirector
8,492
0.0252%
$61.04
$518,352
+29.63%
2025-07-24SaleBitterman Kevindirector
13,033
0.038%
$61.17
$797,229
+25.59%
Total: 81
*Gray background shows transactions not older than one year

Insider Historical Profitability

33.26%
ORBIMED ADVISORS LLCdirector
186541
0.4941%
$14.24M17
+10.7%
Ashiya Monadirector
186541
0.4941%
$14.24M17
+10.7%
Quisel John DChief Executive Officer
171828
0.4552%
$13.12M07
Savage William JacobChief Medical Officer
75702
0.2005%
$5.78M09
Stephenson PamelaChief Commercial Officer
69529
0.1842%
$5.31M01
Franchi Jean M.Chief Financial Officer
63499
0.1682%
$4.85M04
Yu Jonathan Yen-WenChief Operating Officer
40555
0.1074%
$3.1M02
Khara RahulChief Legal Officer
37793
0.1001%
$2.88M05
Bitterman Kevindirector
14013
0.0371%
$1.07M118
+10.7%
AI DMI LLC10 percent owner
3141759
8.3225%
$239.81M10
+100.92%
Atlas Venture Fund X, L.P.10 percent owner
198326
0.5254%
$15.14M07
White William Richarddirector
0
0%
$0010
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$11,588,217
69
42.07%
$2.9B
$11,583,737
45
49.75%
$2.63B
$62,927,079
29
14.02%
$2.28B
$61,703,557
26
40.25%
$3.09B
$7,033,101
22
-12.19%
$2.37B
$27,105,902
21
-16.06%
$2.83B
$137,061,250
16
23.01%
$3.21B
$174,105,409
15
10.88%
$2.75B
$73,814,940
15
-4.77%
$2.67B
$92,580,864
14
-1.28%
$3.03B
$45,445,266
9
-24.96%
$3.05B
$130,038,539
8
26.82%
$2.46B
$32,575,266
8
37.03%
$2.9B
$91,589,325
7
-6.97%
$2.91B
$4,623,072
7
11.07%
$2.34B
Disc Medicine, Inc.
(IRON)
$24,000,085
4
33.26%
$2.88B
$142,493,653
3
4.30%
$3.09B
$9,900,000
1
-7.19%
$3.16B
$5,000,000
1
-22.84%
$2.83B

IRON Institutional Investors: Active Positions

Increased Positions87+59.59%5M+15.47%
Decreased Positions56-38.36%5M-13.44%
New Positions24New1MNew
Sold Out Positions10Sold Out742,726Sold Out
Total Postitions177+21.23%35M+2.02%

IRON Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Fmr Llc$390,322.0012.99%4.94M+2M+52.05%2025-09-30
Atlas Venture Life Science Advisors, Llc$169,460.005.64%2.14M-241,839-10.14%2025-09-30
Blackrock, Inc.$159,705.005.31%2.02M-25,544-1.25%2025-09-30
Ra Capital Management, L.P.$124,733.004.15%1.58M00%2025-09-30
Vanguard Group Inc$114,527.003.81%1.45M+51,323+3.67%2025-09-30
Frazier Life Sciences Management, L.P.$113,774.003.79%1.44M-216,300-13.07%2025-09-30
Orbimed Advisors Llc$111,914.003.72%1.42M00%2025-09-30
Wellington Management Group Llp$111,523.003.71%1.41M-22,013-1.54%2025-09-30
Price T Rowe Associates Inc /Md/$104,907.003.49%1.33M-189,196-12.48%2025-09-30
State Street Corp$82,696.002.75%1.05M+115,829+12.46%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.